^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

Yescarta (axicabtagene ciloleucel)

i
Other names: KTE-C19 CAR, anti-CD19 chimeric antigen receptor transduced T cells, KTEC19, KTE-C19, KTE-C19 chimeric antigen receptor T cell therapy, FKC876, FKC-876, anti-CD19-CAR PBL, anti-cluster of differentiation 19 (CD19)-CAR PBL, FKC 876
Company:
Cabaret Biotech, Fosun Kite, Gilead, National Cancer Institute
Drug class:
CD19-targeted CAR-T immunotherapy
Related drugs:
8d
Journal
|
IL6 (Interleukin 6)
|
Yescarta (axicabtagene ciloleucel)
16d
RG1006269: Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma (clinicaltrials.gov)
P1/2, N=50, Recruiting, University of Washington | Trial completion date: Mar 2030 --> Mar 2031 | Trial primary completion date: Mar 2025 --> Mar 2026
Trial completion date • Trial primary completion date • Combination therapy • CAR T-Cell Therapy
|
CD4 (CD4 Molecule)
|
Calquence (acalabrutinib) • Yescarta (axicabtagene ciloleucel)
26d
Severe cytopenia after chimeric antigen receptor-T cell driven by large granular lymphocytes and responsive to steroids. (PubMed, Br J Haematol)
Here, we report three cases of severe ICAHT after axicabtagene-ciloleucel (axi-cel) for diffuse large B-cell lymphoma showing an expansion of large granular lymphocyte in the bone marrow with a CD3/CD57-positive non-CAR-T immunophenotype. We show that it is possible to treat them with low-dose steroids, obtaining a striking resolution of cytopenias with no deleterious impact on the underlying malignancy.
Journal • CAR T-Cell Therapy
|
B3GAT1 (Beta-1,3-Glucuronyltransferase 1)
|
Yescarta (axicabtagene ciloleucel)
30d
Enrollment open
|
Yescarta (axicabtagene ciloleucel)
1m
Addition of nivolumab tailored by expansion of CAR-T cells in patients with stable/progressive large B cell lymphoma at lymphodepletion - a phase 2, prospective interventional study. (PubMed, Transplant Cell Ther)
We conclude that the addition of nivolumab based on CAR-T cell expansion in patients with SD/PD-LBCL is safe and yields promising early response rates.
P2 data • Journal • CAR T-Cell Therapy • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CD27 (CD27 Molecule)
|
PD-1 expression
|
Opdivo (nivolumab) • Yescarta (axicabtagene ciloleucel) • Kymriah (tisagenlecleucel-T)
1m
ALYCANTE: Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B Lymphoma Ineligible to Autologous Stem Cell Transplantation (clinicaltrials.gov)
P2, N=62, Active, not recruiting, The Lymphoma Academic Research Organisation | Trial completion date: Jun 2024 --> Jun 2026
Trial completion date
|
Yescarta (axicabtagene ciloleucel)
1m
ZUMA-24: Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell Lymphoma (clinicaltrials.gov)
P2, N=30, Active, not recruiting, Kite, A Gilead Company | Trial primary completion date: Mar 2026 --> Sep 2024
Trial primary completion date
|
BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
|
BCL6 rearrangement • BCL2 rearrangement
|
cyclophosphamide • Yescarta (axicabtagene ciloleucel) • fludarabine IV
2ms
New P4 trial
|
Yescarta (axicabtagene ciloleucel)
2ms
Baseline Immune State and T-cell Clonal Kinetics are Associated with Durable Response to CAR-T Therapy in Large B-cell Lymphoma. (PubMed, Blood)
We analyzed serial peripheral blood samples ranging from day of apheresis (day -28/baseline) to 28 days after CAR-T infusion from 50 patients with LBCL treated with axicabtagene ciloleucel (axi-cel) by integrating single cell RNA and TCR sequencing (scRNA-seq/scTCR-seq), flow cytometry, and mass cytometry (CyTOF) to characterize features associated with response to CAR-T...Our results suggest that patients' immunologic state at baseline affects likelihood of response to CAR-T through both modulation of the T cell apheresis product composition and promoting a more favorable circulating immune compartment prior to therapy. These baseline immunologic features, measured readily in the clinical setting prior to CAR-T, can be applied to predict response to therapy.
Journal
|
CD8 (cluster of differentiation 8)
|
Yescarta (axicabtagene ciloleucel)
2ms
CD19 CAR-T treatment shows limited efficacy in r/r DLBCL with double expression and TP53 alterations. (PubMed, Cytotherapy)
Our study suggests that r/r DLBCL patients with both DE status and TP53 alterations treated with CAR-T therapy are more likely to have a poorer clinical prognosis. However, CAR-T therapy has the potential to improve the prognosis of patients with only TP53 alterations or DE status to be similar to that of patients without these abnormalities.
Journal • IO biomarker
|
TP53 (Tumor protein P53) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2)
|
cyclophosphamide • Yescarta (axicabtagene ciloleucel) • fludarabine IV • Carteyva (relmacabtagene autoleucel)
3ms
New trial
|
Yescarta (axicabtagene ciloleucel)
3ms
Tocilizumab Prophylaxis Following Axicabtagene Ciloleucel in Relapsed or Refractory Large B-cell Lymphoma. (PubMed, Transplant Cell Ther)
Based on these findings, prophylactic tocilizumab is not recommended to prevent CAR T-cell-related adverse events, and beneficial effects of prophylactic levetiracetam remain uncertain in patients with R/R LBCL.
Journal
|
IL6R (Interleukin 6 receptor)
|
Yescarta (axicabtagene ciloleucel) • Actemra IV (tocilizumab)
3ms
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy. (clinicaltrials.gov)
P2, N=40, Recruiting, M.D. Anderson Cancer Center | Trial primary completion date: Sep 2024 --> Aug 2026
Trial primary completion date
|
Yescarta (axicabtagene ciloleucel)
3ms
Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy (clinicaltrials.gov)
P2, N=27, Recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial completion date: Nov 2026 --> Dec 2025
Trial completion date • CAR T-Cell Therapy
|
JAK1 (Janus Kinase 1) • CRP (C-reactive protein)
|
Yescarta (axicabtagene ciloleucel) • itacitinib (INCB039110)
3ms
Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL (clinicaltrials.gov)
P2, N=27, Recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial completion date: Oct 2027 --> Jul 2026 | Trial primary completion date: Oct 2027 --> Jul 2025
Trial completion date • Trial primary completion date • CAR T-Cell Therapy
|
Yescarta (axicabtagene ciloleucel)
3ms
AMC-112: Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
P1, N=20, Recruiting, AIDS Malignancy Consortium | Not yet recruiting --> Recruiting
Enrollment open • Immune cell
|
CD4 (CD4 Molecule)
|
cyclophosphamide • Yescarta (axicabtagene ciloleucel) • fludarabine IV
3ms
Novel prognostic scoring systems for severe CRS and ICANS after anti-CD19 CAR T cells in large B-cell lymphoma. (PubMed, J Hematol Oncol)
Patients with a CRS-PSS score > 2 had significantly higher risk to develop grade ≥ 3 ICANS. Both scores were externally validated in international cohorts of patients treated with tisa-cel or axi-cel.
Journal • CAR T-Cell Therapy
|
CRP (C-reactive protein)
|
Yescarta (axicabtagene ciloleucel) • Kymriah (tisagenlecleucel-T)
4ms
New trial
|
BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
|
Yescarta (axicabtagene ciloleucel)
4ms
Evaluate the non-interventional clinical study of Axicabtagene injection in the treatment of relapsed or refractory non-Hodgkin's lymphoma (ChiCTR2100047990)
P4, N=200, Recruiting, Union Hospital of Tongji Medical College of Huazhong University of Science and Technology; Fosun Kite Biotechnology Co., Ltd | Not yet recruiting --> Recruiting
Enrollment open
|
Yescarta (axicabtagene ciloleucel)
4ms
A Single-arm, Multicenter, Open Clinical Study to Evaluate the Efficacy of FKC876 in Treatment of Adult Patients with Relapsed/Refractory Indolent Non-Hodgkin’s Lymphoma (iNHL) (ChiCTR2200058587)
P2, N=32, Recruiting, The First Affiliated Hospital of Soochow University; Fosun Kite Biotechnology Co., Ltd. | Not yet recruiting --> Recruiting
Enrollment open
|
Yescarta (axicabtagene ciloleucel)
4ms
Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma (clinicaltrials.gov)
P2, N=36, Recruiting, Jonsson Comprehensive Cancer Center | Trial completion date: Jun 2025 --> Jun 2026 | Trial primary completion date: Jun 2024 --> Jun 2025
Trial completion date • Trial primary completion date • CAR T-Cell Therapy
|
IL6 (Interleukin 6)
|
cyclophosphamide • Yescarta (axicabtagene ciloleucel) • fludarabine IV • Kineret (anakinra)
5ms
Phase classification • Combination therapy
|
BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
|
cyclophosphamide • Yescarta (axicabtagene ciloleucel) • fludarabine IV • utomilumab (PF-05082566)
5ms
Axi-cel in CNS Lymphoma (clinicaltrials.gov)
P1, N=18, Active, not recruiting, Dana-Farber Cancer Institute | Trial primary completion date: Jun 2024 --> Dec 2024
Trial primary completion date • CAR T-Cell Therapy
|
cyclophosphamide • Yescarta (axicabtagene ciloleucel) • fludarabine IV
5ms
Malnutrition and cachexia are associated with poor CAR T-cell therapy outcomes including survival. (PubMed, Clin Nutr ESPEN)
Pre-treatment malnutrition and cachexia was significantly associated with adverse CAR T patient outcomes, including mGPS cachexia status independently associated with inferior overall survival. Further research in this novel space is essential to confirm the extent and impact of nutritional issues, to assist with implementing dietetic pathways, and to identify potential interventions with a view to optimising outcomes.
Journal • CAR T-Cell Therapy
|
CRP (C-reactive protein)
|
Yescarta (axicabtagene ciloleucel) • Kymriah (tisagenlecleucel-T)
5ms
Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy. (PubMed, N Engl J Med)
Our results highlight the rarity of second tumors and provide a framework for defining clonal relationships and viral vector monitoring. (Funded by the National Cancer Institute and others.).
Journal • CAR T-Cell Therapy
|
DNMT3A (DNA methyltransferase 1) • TET2 (Tet Methylcytosine Dioxygenase 2)
|
Yescarta (axicabtagene ciloleucel)
5ms
Cost-effectiveness of treating relapsed or refractory 3L+ follicular lymphoma with axicabtagene ciloleucel vs mosunetuzumab in the United States. (PubMed, Front Immunol)
Scenarios one and two resulted in ICERs of $105,353 and $102,695, respectively. This study finds that axi-cel is cost-effective compared to mosun at the commonly cited $150,000/QALY US willingness-to-pay threshold, with robust results across a range of sensitivity analyses accounting for parameter uncertainty.
Clinical • Journal • HEOR • Cost-effectiveness • Cost effectiveness
|
CD20 (Membrane Spanning 4-Domains A1)
|
Yescarta (axicabtagene ciloleucel) • Lunsumio (mosunetuzumab-axgb)
5ms
Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy (clinicaltrials.gov)
P2, N=27, Recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial completion date: May 2026 --> Nov 2026 | Trial primary completion date: Jun 2024 --> Oct 2024
Trial completion date • Trial primary completion date • CAR T-Cell Therapy
|
JAK1 (Janus Kinase 1) • CRP (C-reactive protein)
|
Yescarta (axicabtagene ciloleucel) • itacitinib (INCB039110)
5ms
ZUMA-1: Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma (clinicaltrials.gov)
P1/2, N=307, Completed, Kite, A Gilead Company | Trial primary completion date: Sep 2020 --> Jul 2023
Trial primary completion date
|
cisplatin • carboplatin • gemcitabine • Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • oxaliplatin • etoposide IV • vincristine • Yescarta (axicabtagene ciloleucel) • prednisone • dexamethasone • bendamustine • fludarabine IV • Actemra IV (tocilizumab)
6ms
Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma (clinicaltrials.gov)
P2, N=22, Completed, M.D. Anderson Cancer Center | Active, not recruiting --> Completed | Trial completion date: Jan 2025 --> May 2024 | Trial primary completion date: Jan 2025 --> May 2024
Trial completion • Trial completion date • Trial primary completion date
|
cyclophosphamide • Yescarta (axicabtagene ciloleucel) • fludarabine IV • Kineret (anakinra)
6ms
Identification of a clinically efficacious CAR T cell subset in diffuse large B cell lymphoma by dynamic multidimensional single-cell profiling. (PubMed, Nat Cancer)
Using independent datasets, we validate that CD8-fit T cells (1) are present premanufacture and are associated with clinical responses in individuals treated with axicabtagene ciloleucel, (2) longitudinally persist in individuals after treatment with CAR T cells and (3) are tumor migrating cytolytic cells capable of intratumoral expansion in solid tumors. Our results demonstrate the power of multimodal integration of single-cell functional assessments for the discovery and application of CD8-fit T cells as a T cell subset with optimal fitness in cell therapy.
Journal • CAR T-Cell Therapy
|
CD8 (cluster of differentiation 8)
|
Yescarta (axicabtagene ciloleucel)
6ms
Enrollment open
|
Gazyva (obinutuzumab) • Yescarta (axicabtagene ciloleucel) • Tecartus (brexucabtagene autoleucel) • Columvi (glofitamab-gxbm)
7ms
Efficacy and safety of bendamustine for lymphodepletion before lisocabtagene maraleucel. (PubMed, J Hematol Oncol)
Bendamustine has been retrospectively shown to be an effective and safe lymphodepletion regimen prior to the anti-CD19 chimeric antigen receptor T cell (CART) products tisagenlecleucel and axicabtagene ciloleucel, as well as the anti-BCMA CART products idecabtagene vicleucel and ciltacabtagene autoleucel. Neutropenia ≥ grade 3 was observed in 29.0% of patients; thrombocytopenia ≥ grade 3 occurred in 9.7%. In conclusion, bendamustine lymphodepletion before liso-cel appears to be a strategy that can drive tumor responses while ensuring a mild toxicity profile.
Journal
|
CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
|
Yescarta (axicabtagene ciloleucel) • Breyanzi (lisocabtagene maraleucel) • Kymriah (tisagenlecleucel-T) • bendamustine • Abecma (idecabtagene vicleucel) • Carvykti (ciltacabtagene autoleucel)
7ms
A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity (clinicaltrials.gov)
P2, N=15, Active, not recruiting, Marcela V. Maus, M.D.,Ph.D. | Completed --> Active, not recruiting | Trial completion date: Oct 2023 --> Oct 2025 | Trial primary completion date: Oct 2022 --> Oct 2024
Enrollment closed • Trial completion date • Trial primary completion date • CAR T-Cell Therapy
|
Yescarta (axicabtagene ciloleucel) • Kineret (anakinra)
7ms
Context matters: Tumor microenvironments impact cellular therapy success. (PubMed, Cell Rep Med)
present data from pretreatment tumor biopsies taken on the ZUMA-7 trial. Their results identify tumor microenvironment (TME) contexts and level of CD19 expression as prognostic indicators for responses to axicabtagene ciloleucel (axi-cel).
Journal
|
CD19 (CD19 Molecule)
|
CD19 expression
|
Yescarta (axicabtagene ciloleucel)
7ms
Early CAR- CD4+ T-lymphocytes recovery following CAR-T cell infusion: A worse outcome in diffuse large B cell lymphoma. (PubMed, EJHaem)
Among possible determinants of CD4+ T cell recovery, we recognized infusion of a 4-1BB product (tisagenlecleucel, TSA) in comparison with a CD28 (axicabtagene/brexucabtagene, AXI/BRX) (hazard ratio [HR] [95% CI]: 5.79 [1.16-24.12] p = 0.016). We conclude that a faster CAR- CD4+ T cell recovery is associated with TSA as compared to AXI/BRX. Month-1 CAR- CD4+ T cell subset recovery could represent a "red flag" for CAR-T cell therapy failure in DLBCL patients.
Journal • CAR T-Cell Therapy
|
CD4 (CD4 Molecule)
|
Yescarta (axicabtagene ciloleucel) • Kymriah (tisagenlecleucel-T) • Tecartus (brexucabtagene autoleucel)
7ms
Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells (clinicaltrials.gov)
P2, N=700, Enrolling by invitation, Kite, A Gilead Company | Trial completion date: Mar 2041 --> Dec 2040 | Trial primary completion date: Mar 2041 --> Dec 2040
Trial completion date • Trial primary completion date
|
Yescarta (axicabtagene ciloleucel) • Tecartus (brexucabtagene autoleucel) • KITE-222 • KITE-363 • KITE-439 • KITE-585 • KITE-718
7ms
Enrollment closed
|
BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
|
BCL6 rearrangement • BCL2 rearrangement
|
cyclophosphamide • Yescarta (axicabtagene ciloleucel) • fludarabine IV
7ms
ZUMA-22: Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma (clinicaltrials.gov)
P3, N=230, Recruiting, Kite, A Gilead Company | Trial completion date: Jan 2031 --> Oct 2030 | Trial primary completion date: Jan 2031 --> Oct 2030
Trial completion date • Trial primary completion date
|
Rituxan (rituximab) • lenalidomide • doxorubicin hydrochloride • cyclophosphamide • vincristine • Yescarta (axicabtagene ciloleucel) • prednisone • bendamustine • fludarabine IV
7ms
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
P2, N=396, Recruiting, SWOG Cancer Research Network | Trial primary completion date: Dec 2024 --> Dec 2025
Trial primary completion date • CAR T-Cell Therapy
|
cyclophosphamide • Yescarta (axicabtagene ciloleucel) • Breyanzi (lisocabtagene maraleucel) • Kymriah (tisagenlecleucel-T) • fludarabine IV • Polivy (polatuzumab vedotin-piiq) • Lunsumio (mosunetuzumab-axgb)
8ms
MT2017-45: CAR-T Cell Therapy for Heme Malignancies (clinicaltrials.gov)
P=N/A, N=144, Active, not recruiting, Masonic Cancer Center, University of Minnesota | Recruiting --> Active, not recruiting | N=240 --> 144 | Trial primary completion date: Jun 2028 --> Feb 2024
Enrollment closed • Enrollment change • Trial primary completion date • CAR T-Cell Therapy
|
CD19 (CD19 Molecule)
|
CD19 expression
|
cyclophosphamide • Yescarta (axicabtagene ciloleucel) • Breyanzi (lisocabtagene maraleucel) • Kymriah (tisagenlecleucel-T) • fludarabine IV • Tecartus (brexucabtagene autoleucel) • Abecma (idecabtagene vicleucel)
8ms
Trial completion date
|
BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
|
BCL6 rearrangement • BCL2 rearrangement • CD20 negative
|
carboplatin • cytarabine • cyclophosphamide • oxaliplatin • Yescarta (axicabtagene ciloleucel) • fludarabine IV • methylprednisolone sodium succinate
8ms
RG1006269: Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma (clinicaltrials.gov)
P1/2, N=50, Recruiting, University of Washington | Trial completion date: Mar 2029 --> Mar 2030 | Trial primary completion date: Mar 2024 --> Mar 2025
Trial completion date • Trial primary completion date • Combination therapy • CAR T-Cell Therapy
|
CD4 (CD4 Molecule)
|
Calquence (acalabrutinib) • Yescarta (axicabtagene ciloleucel)